Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases

Go Wun Choi, Ju Yeun Lee, Min Jung Chang, Young Kyung Kim, Yoonsook Cho, Yun Mi Yu, Euni Lee

Research output: Contribution to journalArticle

Abstract

This study aimed to describe the occurrence and to evaluate the predictive factors of thrombocytopenia caused by parenteral linezolid in hospitalised patients without haemato-oncologic diseases. Using electronic medical records, a retrospective safety evaluation was performed among all hospitalised adult patients who received parenteral linezolid therapy between January 2005 and June 2016. Of all identified 264 patients with an average age of 63.4 (SD 15.8) years, thrombocytopenia occurred at a rate of 29.2% after an average of 11.2 (SD 7.4) days of the initiation of linezolid therapy. Significant predictive factors for thrombocytopenia included the duration of linezolid therapy longer than or equal to 7 days (adjusted odds ratios [ORs] 7.25, 19.51 and 28.80; 95% confidence intervals [CIs] 1.92-27.38, 4.76-79.95 and 6.48-127.92 for 7-13 days, 14-20 days and ≥21 days, respectively; P < 0.01 for all values), baseline platelet count <150 × 10 3 /mm 3 (adjusted OR, 5.08; 95% CI, 2.06-12.55; P < 0.001), creatinine clearance <30 mL/min (adjusted OR, 4.19; 95% CI, 1.59-11.06; P = 0.004) and concurrent low-dose aspirin therapy (adjusted OR, 2.99; 95% CI, 1.26-7.08; P = 0.013). Baseline platelet count less than 150 × 10 3 /mm 3 was an independent predictor of early-onset (≤6 days) thrombocytopenia (adjusted OR, 5.07; 95% CI, 1.46-17.58; P = 0.011). Closer monitoring of platelet count is required in patients who receive parenteral linezolid therapy for 7 days or more, and have low baseline platelet counts or impaired renal function.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume124
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Linezolid
Thrombocytopenia
Platelets
Platelet Count
Odds Ratio
Confidence Intervals
Electronic medical equipment
Therapeutics
Electronic Health Records
Aspirin
Creatinine
Kidney
Safety

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Choi, Go Wun ; Lee, Ju Yeun ; Chang, Min Jung ; Kim, Young Kyung ; Cho, Yoonsook ; Yu, Yun Mi ; Lee, Euni. / Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. In: Basic and Clinical Pharmacology and Toxicology. 2019 ; Vol. 124, No. 2. pp. 228-234.
@article{c30e81b834f54f528f6a83c5c5dd0c04,
title = "Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases",
abstract = "This study aimed to describe the occurrence and to evaluate the predictive factors of thrombocytopenia caused by parenteral linezolid in hospitalised patients without haemato-oncologic diseases. Using electronic medical records, a retrospective safety evaluation was performed among all hospitalised adult patients who received parenteral linezolid therapy between January 2005 and June 2016. Of all identified 264 patients with an average age of 63.4 (SD 15.8) years, thrombocytopenia occurred at a rate of 29.2{\%} after an average of 11.2 (SD 7.4) days of the initiation of linezolid therapy. Significant predictive factors for thrombocytopenia included the duration of linezolid therapy longer than or equal to 7 days (adjusted odds ratios [ORs] 7.25, 19.51 and 28.80; 95{\%} confidence intervals [CIs] 1.92-27.38, 4.76-79.95 and 6.48-127.92 for 7-13 days, 14-20 days and ≥21 days, respectively; P < 0.01 for all values), baseline platelet count <150 × 10 3 /mm 3 (adjusted OR, 5.08; 95{\%} CI, 2.06-12.55; P < 0.001), creatinine clearance <30 mL/min (adjusted OR, 4.19; 95{\%} CI, 1.59-11.06; P = 0.004) and concurrent low-dose aspirin therapy (adjusted OR, 2.99; 95{\%} CI, 1.26-7.08; P = 0.013). Baseline platelet count less than 150 × 10 3 /mm 3 was an independent predictor of early-onset (≤6 days) thrombocytopenia (adjusted OR, 5.07; 95{\%} CI, 1.46-17.58; P = 0.011). Closer monitoring of platelet count is required in patients who receive parenteral linezolid therapy for 7 days or more, and have low baseline platelet counts or impaired renal function.",
author = "Choi, {Go Wun} and Lee, {Ju Yeun} and Chang, {Min Jung} and Kim, {Young Kyung} and Yoonsook Cho and Yu, {Yun Mi} and Euni Lee",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/bcpt.13123",
language = "English",
volume = "124",
pages = "228--234",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "2",

}

Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. / Choi, Go Wun; Lee, Ju Yeun; Chang, Min Jung; Kim, Young Kyung; Cho, Yoonsook; Yu, Yun Mi; Lee, Euni.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 124, No. 2, 01.02.2019, p. 228-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases

AU - Choi, Go Wun

AU - Lee, Ju Yeun

AU - Chang, Min Jung

AU - Kim, Young Kyung

AU - Cho, Yoonsook

AU - Yu, Yun Mi

AU - Lee, Euni

PY - 2019/2/1

Y1 - 2019/2/1

N2 - This study aimed to describe the occurrence and to evaluate the predictive factors of thrombocytopenia caused by parenteral linezolid in hospitalised patients without haemato-oncologic diseases. Using electronic medical records, a retrospective safety evaluation was performed among all hospitalised adult patients who received parenteral linezolid therapy between January 2005 and June 2016. Of all identified 264 patients with an average age of 63.4 (SD 15.8) years, thrombocytopenia occurred at a rate of 29.2% after an average of 11.2 (SD 7.4) days of the initiation of linezolid therapy. Significant predictive factors for thrombocytopenia included the duration of linezolid therapy longer than or equal to 7 days (adjusted odds ratios [ORs] 7.25, 19.51 and 28.80; 95% confidence intervals [CIs] 1.92-27.38, 4.76-79.95 and 6.48-127.92 for 7-13 days, 14-20 days and ≥21 days, respectively; P < 0.01 for all values), baseline platelet count <150 × 10 3 /mm 3 (adjusted OR, 5.08; 95% CI, 2.06-12.55; P < 0.001), creatinine clearance <30 mL/min (adjusted OR, 4.19; 95% CI, 1.59-11.06; P = 0.004) and concurrent low-dose aspirin therapy (adjusted OR, 2.99; 95% CI, 1.26-7.08; P = 0.013). Baseline platelet count less than 150 × 10 3 /mm 3 was an independent predictor of early-onset (≤6 days) thrombocytopenia (adjusted OR, 5.07; 95% CI, 1.46-17.58; P = 0.011). Closer monitoring of platelet count is required in patients who receive parenteral linezolid therapy for 7 days or more, and have low baseline platelet counts or impaired renal function.

AB - This study aimed to describe the occurrence and to evaluate the predictive factors of thrombocytopenia caused by parenteral linezolid in hospitalised patients without haemato-oncologic diseases. Using electronic medical records, a retrospective safety evaluation was performed among all hospitalised adult patients who received parenteral linezolid therapy between January 2005 and June 2016. Of all identified 264 patients with an average age of 63.4 (SD 15.8) years, thrombocytopenia occurred at a rate of 29.2% after an average of 11.2 (SD 7.4) days of the initiation of linezolid therapy. Significant predictive factors for thrombocytopenia included the duration of linezolid therapy longer than or equal to 7 days (adjusted odds ratios [ORs] 7.25, 19.51 and 28.80; 95% confidence intervals [CIs] 1.92-27.38, 4.76-79.95 and 6.48-127.92 for 7-13 days, 14-20 days and ≥21 days, respectively; P < 0.01 for all values), baseline platelet count <150 × 10 3 /mm 3 (adjusted OR, 5.08; 95% CI, 2.06-12.55; P < 0.001), creatinine clearance <30 mL/min (adjusted OR, 4.19; 95% CI, 1.59-11.06; P = 0.004) and concurrent low-dose aspirin therapy (adjusted OR, 2.99; 95% CI, 1.26-7.08; P = 0.013). Baseline platelet count less than 150 × 10 3 /mm 3 was an independent predictor of early-onset (≤6 days) thrombocytopenia (adjusted OR, 5.07; 95% CI, 1.46-17.58; P = 0.011). Closer monitoring of platelet count is required in patients who receive parenteral linezolid therapy for 7 days or more, and have low baseline platelet counts or impaired renal function.

UR - http://www.scopus.com/inward/record.url?scp=85054626407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054626407&partnerID=8YFLogxK

U2 - 10.1111/bcpt.13123

DO - 10.1111/bcpt.13123

M3 - Article

VL - 124

SP - 228

EP - 234

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 2

ER -